Evaluation of an alpha-cypermethrin + PBO mixture long-lasting insecticidal net VEERALIN® LN against pyrethroid resistant Anopheles gambiae s.s.: an experimental hut trial in M'bé, central Côte d'Ivoire. by Oumbouke, Welbeck A et al.
LSHTM Research Online
Oumbouke, Welbeck A; Rowland, Mark; Koffi, Alphonsine A; Alou, Ludovic PA; Camara, Soromane;
N’Guessan, Raphael; (2019) Evaluation of an alpha-cypermethrin + PBO mixture long-lasting insec-
ticidal net VEERALIN R© LN against pyrethroid resistant Anopheles gambiae s.s.: an experimental
hut trial in M’bé, central Côte d’Ivoire. Parasites & vectors, 12 (1). p. 544. ISSN 1756-3305 DOI:
https://doi.org/10.1186/s13071-019-3796-x
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655363/
DOI: https://doi.org/10.1186/s13071-019-3796-x
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
Oumbouke et al. Parasites Vectors          (2019) 12:544  
https://doi.org/10.1186/s13071-019-3796-x
RESEARCH
Evaluation of an alpha-cypermethrin + PBO 
mixture long-lasting insecticidal net VEERALIN® 
LN against pyrethroid resistant Anopheles 
gambiae s.s.: an experimental hut trial in M’bé, 
central Côte d’Ivoire
Welbeck A. Oumbouke1,2*, Mark Rowland1, Alphonsine A. Koffi2, Ludovic P. A. Alou2, Soromane Camara2 
and Raphael N’Guessan1,2
Abstract 
Background: Long-lasting insecticidal nets (LLINs) are the primary method of malaria prevention. However, the 
widespread resistance to pyrethroids among major malaria vector species represents a significant threat to the 
continued efficacy of pyrethroid LLIN. Piperonyl butoxide (PBO) is a synergist that inhibits the activity of metabolic 
enzymes of the cytochrome P450 family known to detoxify insecticides including pyrethroids. Synergist LLIN incorpo-
rating PBO and a pyrethroid may provide improved control compared to pyrethroid-only LLIN.
Methods: The efficacy of VEERALIN® LN (VKA polymers Pvt Ltd, India), an alpha-cypermethrin PBO synergist net was 
evaluated in experimental huts in M’bé, central Côte d’Ivoire against wild pyrethroid resistant Anopheles gambiae s.s. 
Comparison was made with a standard alpha-cypermethrin-treated net (MAGNet® LN, VKA polymers Pvt Ltd, India). 
Nets were tested unwashed and after 20 standardized washes.
Results: VEERALIN® LN demonstrated improved efficacy compared to MAGNet® LN against wild free-flying 
pyrethroid-resistant An. gambiae s.s. Before washing, VEERALIN® LN produced mortality of An. gambiae s.s. (51%) 
significantly higher than the standard pyrethroid-only net (29%) (P < 0.0001). Although there was a significant reduc-
tion in mortality with both LLINs after 20 washes, VEERALIN® LN remained superior in efficacy to MAGNet® LN (38 vs 
17%) (P < 0.0001). Blood-feeding was significantly inhibited with both types of insecticide-treated nets relative to the 
untreated control net (P < 0.0001). Unwashed VEERALIN® LN induced significantly higher blood-feeding inhibition of 
An. gambiae s.s. (62.6%) compared to MAGNet® LN (35.4%) (P < 0.001). The difference persisted after washing, as there 
was no indication that either LLIN lost protection against biting or blood-feeding. The level of personal protection 
derived from the use of VEERALIN® LN was high (87%) compared to MAGNet® LN (66–69%) whether unwashed or 
washed. The AI content of VEERALIN® LN after 20 washes decreased from 6.75 to 6.03 g/kg for alpha-cypermethrin 
and from 2.95 to 2.64 g/kg for PBO, corresponding to an overall retention of 89% for each compound.
Conclusions: The addition of the synergist PBO to pyrethroid net greatly improved protection and control of 
pyrethroid-resistant An. gambiae s.s. The pyrethroid-PBO VEERALIN® LN has the potential to reduce transmission in 
areas compromised by pyrethroid resistance.
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Background
Long-lasting insecticidal nets (LLINs) are considered 
best practice for malaria prevention in the majority of 
African countries. The estimated proportion of people 
sleeping under nets in sub-Saharan Africa rose to 53% in 
2015 from a low of less than 2% in 2000. This increase in 
net use has resulted in about half a billion clinical malaria 
cases averted over the same time period [1]. This substan-
tial reduction in malaria cases justifies ongoing efforts 
by National Malaria Control Programmes (NMCPs) to 
increase ownership and use of LLIN.
Despite the significant headway made, malaria remains 
a major public health problem in many countries. Recent 
estimates from the WHO World Malaria Report indicate 
that progress has stalled between 2015 and 2017, with 
some countries even reporting an increase in the number 
of cases [2]. One potential factor contributing to this is 
the rise in resistance to pyrethroid insecticides in malaria 
vectors across Africa. Although some malaria and health 
facility surveys in Benin have not provided evidence that 
resistance is adversely affecting malaria transmission or 
burden [3, 4], household and hut trials [5, 6] indicate that 
pyrethroid resistance can significantly reduce the efficacy 
of standard LLIN for vector control and personal protec-
tion. While findings from these malaria and health facil-
ity surveys in Benin suggested no association between 
pyrethroid resistance and malaria transmission, these 
are observational studies and therefore provide no con-
clusive evidence on the impact of resistance. Moreover, 
malaria prevalence remains high in many areas of Benin 
despite the widespread use of LLIN. This emphasises the 
need for additional control measures to improve control 
and reduce malaria transmission.
Although LLIN may provide some protection against 
insecticide-resistant Anopheles mosquitoes, this may 
depend on the frequency and strength of the resist-
ance [7–9]. To meet the resistance challenge and restore 
malaria vector control, new active ingredients are being 
developed and tested. A new class of net combines two 
compounds: the pyrethroid and the synergist pipero-
nyl butoxide (PBO) for improved control of pyrethroid-
resistant anopheline mosquitoes. PBO is an insecticide 
synergist which inhibits the action of resistance-asso-
ciated metabolic enzymes of the cytochrome P450 fam-
ily [10]. The inhibition of P450 enzymes by the PBO 
results in the pyrethroid on the net being available to 
induce excito-repellency and mortality. The role of these 
enzymes in the detoxification of insecticides including 
pyrethroids and to cause resistance is well documented 
[11–14]. The addition of PBO to pyrethroid net as a strat-
egy to overcome resistance especially in areas where this 
is driven by overexpression of P450 enzymes known to 
metabolise pyrethroids has been demonstrated in a range 
of experimental hut trials across Africa [15–19]. Simula-
tion modelling suggests that a switch in net policy toward 
pyrethroid-PBO net would result in up to 0.5 clini-
cal malaria cases averted per 1000 people per year [20]. 
Pyrethroid-PBO net was given World Health Organisa-
tion (WHO) policy recommendation as a new class in 
2017 based on epidemiological data from a cluster rand-
omized trial in Muleba, Tanzania [21], which showed that 
Olyset® Plus LN (Sumitomo Chemicals Co. Ltd, Tokyo, 
Japan) reduced malaria-infection prevalence by 33% 
over 21 months of use compared to the standard LLIN, 
Olyset® Net, under a scenario of high pyrethroid resist-
ance and net use. A recent Cochrane review predicted 
that PBO-pyrethroid LLIN is expected to be more effec-
tive in areas of moderate to high resistance mediated by 
metabolic resistance than in settings of low or no insecti-
cide resistance [22].
The recommendation of new product class applies 
to all pyrethroid-PBO nets prequalified by the WHO 
[23]. All of these products differ from Olyset® Plus in 
terms of their design/specifications, which in turn is 
likely to affect their field performance. Key differences 
between these products include the spatial location 
of the PBO (all net panels or just the top panel), PBO 
loading dose, type and concentration of pyrethroid 
and wash-fastness and bioavailability of PBO or part-
ner pyrethroid. VEERALIN® LN (VKA polymers Ltd, 
Tamil Nadu, India) is a new PBO-alphacypermethrin 
synergist LLIN that contains PBO on all net panels and 
recently acquired WHO interim recommendation. The 
Vector Control Product Evaluation Centre (VCPEC) 
based within Institut Pierre Richet (IPR) in Bouaké, 
central Côte d’Ivoire was therefore commissioned by 
the WHO to undertake a phase-2 experimental hut 
study of VEERALIN® LN in an area of high pyrethroid 
resistance mostly mediated by cytochrome P450 meta-
bolic mechanisms.
Methods
Study area and experimental huts
The hut trial was conducted at the M’bé field station in 
central Côte d’Ivoire, 40  km south of Bouaké city. The 
site is a large rice irrigated valley producing mostly An. 
coluzzii year round. The mosquito population from the 
site has developed resistance to multiple insecticide 
classes. Resistance mechanisms include target site insen-
sitivity (1014F and Ace-1) [24] and increased activities of 
insecticide-metabolizing enzymes (esterases, oxidases 
and GSTs) [25] including highly overexpressed CYP6P3 
(Oumbouke and N’Guessan, in preparation). A recent 
investigation into the level of resistance to pyrethroids in 
Anopheles-mosquitoes from the study area reported over 
1700-fold resistance to deltamethrin [26].
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The West African style experimental huts were used 
for the field trial [27]. They were made of concrete bricks, 
with roofs of corrugated iron, ceilings lined with plastic 
sheeting and the interior walls plastered with cement. 
Each hut was built on a concrete base surrounded by a 
water-filled moat to prevent entry of mosquito predators. 
Mosquitoes enter the hut through four 1-cm wide win-
dow slits, located on three sides of the hut. Mosquitoes 
exiting the hut are caught in a veranda trap located on 
the fourth side.
WHO susceptibility assays
To determine the prevalence of resistance to pyrethroids, 
WHO cylinder assays were conducted using papers 
treated with diagnostic concentration of 0.05% alpha-
cypermethrin, the same pyrethroid used in MAGNet® 
and VEERALIN® LLINs. WHO susceptibility tests were 
performed using 2–3 day-old adult female mosquitoes, 
collected as larvae from the M’bé field station. Four 
replicates of 25 female mosquitoes were tested in cyl-
inder assays and mortality was scored 24 h after expo-
sure. Exposure of the susceptible An. gambiae strain to 
alpha-cypermethrin treated paper in cylinder tube was 
conducted to check the quality of the insecticide-treated 
paper. Mosquitoes exposed to untreated paper served as 
control.
LLINs and washing procedure
MAGNet® LN is a long-lasting net containing 5.8  g/kg 
alpha-cypermethrin incorporated in monofilament, high-
density polyethylene (HDPE), 150-denier manufactured 
by VKA polymers. MAGNet® LN received full WHOPES 
recommendation in 2011 [28].
VEERALIN® LN is a long-lasting net manufactured 
by VKA polymers Pvt Ltd, India. Alpha-cypermethrin is 
incorporated into 130-denier monofilament polyethylene 
fibres with a target dose of 6.0 g AI/kg (216 mg AI/m2) 
alpha-cypermethrin and 2.2 g/kg (79.2 mg/m2) PBO.
The nets were washed following the WHOPES-phase 
II washing protocol [29]. The time for regeneration of the 
active ingredients between washes was 1 day for MAG-
Net® LN and 5 days for VEERALIN® LN and therefore 
washing was done every 5 days using 2 g/l soap solution 
(‘savon de Marseille’). One complete washing cycle of each 
net ran for 10 min as follows: each net was first agitated 
for 3 min then left to soak for 4 min and again agitated for 
3  min. Net agitation was performed by stirring each net 
with a wooden pole at 20× rpm. After washing, nets were 
rinsed twice in clean water (10 l per rinsing, i.e. 20  l per 
net). Nets were dried horizontally in the shade, then stored 
at ambient temperature (27 ± 2 °C) between washes.
Net treatments and experimental hut trial procedure
The following treatment arms were trialed in experimen-
tal huts: (i) VEERALIN® LN unwashed; (ii) VEERALIN® 
LN washed 20 times; (iii) MAGNet® LN unwashed; (iv) 
MAGNet® LN washed 20 times; and (v) untreated poly-
ester net (100 denier).
These five treatment arms were randomly allocated to 
5 experimental huts. To account for potential bias due to 
differential hut attractiveness, nets were rotated among 
huts every week according to a balanced Latin square 
scheme. Three nets were used per treatment arm and 
each net was tested within hut on 2 consecutive nights 
during the week. Before the hut trial, holes (16-cm2 in 
diameter) were made in the nets (2 on each side and 1 
on each end) to simulate moderately damaged net during 
field use. The huts were thoroughly cleaned and aired for 
a day at the end of each rotation.
The hut trial spanned 5 weeks (from June to July 2014) 
corresponding to 30  nights of collection per hut. Five 
local human volunteers gave informed consent and 
slept in the huts from 20:00  h to 05:00  h each night. 
To reduce bias resulting from the inherent difference 
in individual attractiveness to host-seeking mosqui-
toes, sleepers were rotated between huts on successive 
nights. Each morning, mosquitoes were collected from 
huts using mouth-operated aspirators from inside the 
room, nets and veranda traps and physiological sta-
tus (live, dead, unfed, blood-fed, semi-gravid, gravid) 
recorded. Mosquitoes were transported to the labora-
tory at the Institut Pierre Richet (IPR), Bouaké, Côte 
d’Ivoire, and identified to the species level. Live female 
mosquitoes were provided with 10% honey solution and 
mortality recorded 24 h later.
Outcome measures
The following outcomes were used to assess the efficacy 
of the treatments as per WHO guidelines [30]: (i) deter-
rence: the percent reduction in the number of mosquitoes 
in treatment hut relative to control hut with untreated 
net; (ii) exit rate; (iii) blood-feeding inhibition rate: the 
percentage reduction in blood-feeding in a hut with 
treated net compared to a hut with untreated net; (iv) 
percentage mortality of adult females; (v) overall insec-
ticidal effect = 100 (Kt − Ku)/Tu, where Kt is the number 
of mosquitoes killed in the treated hut, Ku is the num-
ber dying in the untreated control hut and Tu is the total 
number collected from the control hut [5]; (vi) personal 
protection; percentage reduction in mosquito biting 
in hut with treated net compared to hut with untreated 
net = [1 − (No. of mosquitoes blood-fed in treatment/No. 
of mosquitoes blood-fed in control) × 100].
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Chemical analysis
Determination of alpha-cypermethrin content in 
unwashed and washed MAGNet® and VEERALIN® 
LLINs was performed before and after washing and 
post-trial in accordance with WHO guidelines [29]. 
PBO content was also assessed in VEERALIN® LN. 
A piece of netting measuring 30  cm × 30  cm was cut 
from each of the five locations of each net. Extraction of 
alpha-cypermethrin and PBO was performed using the 
CIPAC method [31]. These compounds were extracted 
by refluxing with xylene for 30  min in the presence of 
dioctyl-phthalate as an internal standard and citric acid. 
Concentrations of alpha-cypermethrin and PBO were 
subsequently measured by Gas Chromatography with 
Flame Ionization Detection (GC-FID).
Cone bioassays
The efficacy of VEERALIN® and MAGNet® LLINs was 
assessed by WHO cone bioassay using susceptible An. 
gambiae before and after washing and after field trial. 
Hundred 2–5 day-old female mosquitoes were subjected 
to 3 min exposure in replicates of 5 mosquitoes per cone 
at 25 ± 2  °C and a relative humidity of 75 ± 10% [30]. 
Mortality was scored 24 h after exposure.
Statistical analysis
Data were entered into an Excel database and subse-
quently imported into the R statistical software version 
2.15.0. for analysis. Proportional outcomes from the 
bioassays (mortality) and the hut trial (exophily, blood-
feeding and mortality) were analysed using generalised 
linear mixed models (GLMMs) with a binomial distribu-
tion and a logit link function was fitted to the data using 
the lme4 package [32]. Net type and hut were included 
as fixed effects, and sleepers and day of mosquito collec-
tion were treated as random effects. Numeric outcomes 
(number entering each hut, feeding and dying) were 
analysed using generalised linear models with a Poisson 
distribution. Pairwise comparisons were performed using 
the multcomp package in R [33].
Results
WHO susceptibility assays
Mortality of the susceptible An. gambiae exposed to 
0.05% alpha-cypermethrin in WHO susceptibility tests 
was 100%. Mortality of An. gambiae  s.s. from M’bé 
exposed to the diagnostic dose of alpha-cypermethrin 
was 68% (n = 108), indicating frequency of resistance to 
pyrethroids of 32% at the study site.
Experimental hut trial
In the 5-week trial, 1054 An. gambiae-mosquitoes were 
collected from the control hut, representing a mean 
number of 29 females per night. Both MAGNet® and 
VEERALIN® LLINs reduced hut entry of An. gam-
biae s.s.; unwashed MAGNet® LN reduced entry by 52% 
and unwashed VEERALIN® LN by 65%. There was no 
evidence of reduced entry after washing the two LLINs 
20 times (Table 1, Additional file 1: Table S1, Additional 
file 2: Table S2).
Relative to the untreated control, the proportions 
of mosquitoes exiting into the verandas was signifi-
cantly greater with each type of insecticide treated net 
by 47–65% (GLMMs, P < 0.0001) (Table  1, Additional 
file 1: Table S1, Additional file 2: Table S2). Before wash-
ing, VEERALIN® and MAGNet® LLINs induced similar 
level of exiting (55%) but after washing exiting was sig-
nificantly greater for VEERALIN® LN (64.7%) than for 
MAGNet® LN (46.8%) (GLMMs, P < 0.0001).
Blood-feeding was significantly inhibited by insecti-
cide-treated net treatment compared to the untreated 
control net (GLMMs, P < 0.0001) (Additional file  1: 
Table  S1, Additional file  2: Table  S2). Unwashed 
VEERALIN® LN induced significantly greater 
Table 1 Experimental hut trial results of unwashed and 20-times washed pyrethroid-PBO and pyrethroid-only LLIN against pyrethroid 
resistant Anopheles gambiae s.s. in M’bé, Côte d’Ivoire
Note: Values in the same row sharing a letter superscript do not differ significantly (P > 0.05, GLMMs)
Untreated net MAGNet® LN 0w MAGNet® LN 20w VEERALIN® LN 0w VEERALIN® LN 20w
Total no. of females caught 1054 506 519 366 377
Mean no. caught/night 29.2a 14.0b 14.4b 10.2c 10.5c
% Deterrence – 52.0 50.7 65.3 64.2
Total no. of females in veranda 248 279 243 203 244
% Exiting (95% CI) 23.5 (21.0–26.1)a 55.1 (50.8–59.5)b 46.8 (42.5–51.1)c 55.5 (50.4–60.6)b 64.7 (59.9–69.5)d
Total no. of blood-fed females 665 206 225 86 89
% Blood-feeding inhibition – 35.5 (31.3–39.7) 31.4 (27.4–35.4) 62.7 (57.7–67.6) 62.6 (57.7–67.5)
% Personal protection – 69.0a 66.2a 87.1b 86.6b
Overall insecticidal effect (%) – 11.8a 6.4b 15.5a 11.5a
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blood-feeding inhibition (62.7%) than MAGNet® LN 
(35.5%) (GLMMs, P < 0.0001) (Table 1, Fig. 1). The dif-
ference persisted after washing, being no loss of protec-
tion with either LN.
All insecticide-treated nets induced greater mortal-
ity than the untreated net (GLMMs, P < 0.0001) (Fig.  2, 
Additional file  1: Table  S1, Additional file  2: Table  S2). 
The unwashed VEERALIN® LN produced mortality of 
51%, although this was significantly greater than that 
induced by MAGNet® LN unwashed (29%) (GLMMs, 
P < 0.0001). After washing, mortality with the PBO-LLIN 
and pyrethroid-only LLIN decreased significantly to 
38.2% for VEERALIN® LN and to 17.3% for MAGNet® 
LN (GLMMs, P < 0.0001); the decrease relative to the 
unwashed net was 24.8% for VEERALIN® LN and 40% 
for MAGNet® LN.
The level of personal protection derived from the use 
of VEERALIN® and MAGNet® LLINs (unwashed and 
Fig. 1 Blood-feeding rates of wild pyrethroid resistant An. gambiae s.s. in experimental huts in M’bé, Côte d’Ivoire. Error bars represent 95% CIs
Fig. 2 Mortality rates of wild pyrethroid resistant An. gambiae s.s. in experimental huts in M’bé, Côte d’Ivoire. Error bars represent 95% CIs
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washed) against An. gambiae-biting ranged between 
86.6–87.1% for VEERALIN® LN and 66.2–69% for MAG-
Net® LN before and after washing. The Overall Killing 
Effect was low (< 16%) across all treatments (Table  1). 
Before washing, VEERALIN® LN induced significantly 
greater overall killing effect (15.5%) compared to MAG-
Net® LN (11.8%), but the difference was not significant 
(GLM, P = 0.41). Although there was a reduction in kill-
ing effect with VEERALIN® (11.5%) and MAGNet® 
(6.4%) LLINs after washing, the decrease in effect was 
only significant with MAGNet® LN (GLM, P = 0.014).
Cone bioassays
Mortality rates of the susceptible An. gambiae were 100% 
with all treated nets assayed in WHO cone at the three 
time points (before, after washing and after field trial).
Chemical analysis
The mean alpha-cypermethrin content in MAGNet® and 
VEERALIN® LLINs and the concentration of the syner-
gist PBO in VEERALIN® LN are presented in Tables  2 
and 3. The initial concentrations of alpha-cypermethrin 
in VEERALIN® LN (6.91 and 6.75 g/kg) and MAGNet® 
LN (6.39 and 5.95 g/kg) were close to the target dose of 
6  g/kg ± 25% for VEERALIN® LN and 5.8  g/kg ± 25% 
for MAGNet® LN, with a within-net variation of less 
than 10%. After washing, the alpha-cypermethrin con-
tent was 6.03 g AI/kg for VEERALIN® LN and 5.65 g AI/
kg for MAGNet® LN corresponding to an overall wash 
retention rate of 89% for VEERALIN® LN and 95% for 
MAGNet® LN. After the 5-week hut trial, there was 
marginal decline in alpha-cypermethrin content (< 15%) 
with either LLIN washed or unwashed. The initial con-
centration of PBO in the unwashed VEERALIN® LN 
(2.63  g/kg) was within the acceptable range of the tar-
get dose of 2.2 g/kg ± 25% but was slightly overdosed in 
the VEERALIN® LN that was destined to be washed 20 
times (2.95 g/kg) (Table 3). After 20 washes, there was a 
decrease in PBO content from 2.95 to 2.64 g AI/kg, cor-
responding to an overall wash retention of 89%. After hut 
trial, there was a small decrease in PBO content (< 20%, 
Table 3).
The decrease in insecticide content after washing of 
VEERALIN® and MAGNet® LLINs was associated with 
a significant decrease in hut mortality; however, personal 
protection was maintained and blood-feeding rates did 
not differ between unwashed and 20 times washed LLINs 
(Tables 2, 3, Figs. 1, 2).
Discussion
Malaria control and pyrethroid-only nets are under 
threat from the increasing prevalence and intensity of 
pyrethroid resistance among malaria vectors [34]. To 
preserve insecticide mosquito net technology, the most 
widely used form of vector-control method, and continue 
progress toward elimination, a class of mosquito net 
incorporating the synergist piperonyl butoxide (PBO) has 
been developed to neutralise some forms of metabolic 
resistance to pyrethroids. On the basis of a cluster ran-
domised trial of Olyset® Plus LN, which demonstrated 
epidemiological evidence of the greater effectiveness of 
pyrethroid-PBO nets in areas of resistance, the WHO 
has conditionally endorsed pyrethroid-PBO nets as a new 
product class for malaria control in areas where resist-
ance is conferred by monooxygenase-based resistance 
mechanisms. Apart from Olyset® Plus LN, there are sev-
eral brands of PBO LLINs, which are being developed 
for approval by the WHO prequalification team. The 
purpose of the present study was to evaluate in experi-
mental huts the efficacy of the pyrethroid-PBO net, 
VEERALIN® LN versus the pyrethroid-only net, MAG-
Net® LN, against pyrethroid-resistant populations of An. 
gambiae s.s. mosquitoes at the M’bé field station in Côte 
d’Ivoire.
In experimental huts, MAGNet® LN, an alpha-cyper-
methrin treated net reduced mosquito survival and 
blood-feeding by approximately 30% for both outcomes. 
This low effect size achieved by MAGNet® LN against 
pyrethroid-resistant An. gambiae s.s. mosquitoes is con-
sistent with findings from previous experimental hut tri-
als with pyrethroid-only LLINs performed at the same 
site [9, 26] and elsewhere [7, 8, 35]. This provides further 
evidence of the poor performance of pyrethroid LLIN 
in areas where malaria-vectors have developed multiple 
mechanisms of pyrethroid resistance [7, 36].
Table 2 Content of alpha-cypermethrin in LLINs used in the 
experimental hut trial
Treatment Concentration of alpha-cypermethrin (g/
kg)
Before trial After washing After trial
MAGNet® LN unwashed 6.39 – 6.47
MAGNet® LN 20 washes 5.95 5.65 5.84
VEERALIN® LN unwashed 6.91 – 7.40
VEERALIN® LN 20 washes 6.75 6.03 5.78
Table 3 Content of piperonyl butoxide (PBO) in VEERALIN® LN 
used in hut trial
Treatment Concentration of PBO (g/kg)
Before trial After washing After trial
VEERALIN® LN unwashed 2.63 – 3.90
VEERALIN® LN 20 washes 2.95 2.64 2.40
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The addition of PBO to alpha-cypermethrin in the net 
was associated with a significant improvement in con-
trol and protection against mosquito bites. VEERALIN® 
LN killed significantly higher proportions (38–51%) of 
the highly resistant population of An. gambiae s.s. com-
pared to MAGNet® LN (17–29%). In previous hut tri-
als comparing pyrethroid-PBO net with pyrethroid-only 
nets, e.g. Olyset® Plus versus Olyset® LLINs or Per-
maNet® 3.0 versus PermaNet® 2.0 LLINs, the difference 
in induced mortality between PBO and standard LLIN 
could not be attributable to PBO conclusively because 
the original concentration of pyrethroid or the bleed 
rate of pyrethroid in the pyrethroid-PBO net differed 
from that in the pyrethroid-only LLIN [16–18]. In the 
present study, the loading dose of alpha-cypermethrin 
in VEERALIN® and MAGNet® LLINs were similar (6 
and 5.8  g/kg, respectively) as was the wash retention of 
alpha-cypermethrin over 20 washes (89 and 95%, respec-
tively). Therefore, the substantial increase in mortality 
observed with VEERALIN® LN was most likely due to 
the PBO component, which is known to inhibit the activ-
ity of key pyrethroid-detoxifying enzymes [10]. However, 
it should be noted that full control of pyrethroid-resistant 
mosquitoes was not achieved with VEERALIN® LN in 
experimental huts. This could be due to the presence of 
resistance mechanisms unaffected by the synergist PBO. 
Another plausible explanation could be that the dose of 
PBO (target dose of 2.2  g/kg) deployed in VEERALIN® 
LN and the bleed rate of PBO to the net surface (wash 
retention index = 98.9% per wash) was insufficient to 
inhibit the range of P450 enzymes associated with resist-
ance in the local An. gambiae s.s. For example, in an area 
of Benin with increased oxidase activity, Olyset® Plus LN 
containing 5 times higher the loading concentration of 
PBO (10 g/kg) and a much higher bleed rate (wash reten-
tion index of 96% per wash) produced significantly higher 
mortality of the local An. gambiae-mosquitoes (67–81%) 
[18] compared to the effect size with VEERALIN® LN 
in the present study. Of course, the resistance situation 
in Benin [37] would not be directly comparable with the 
resistance situation in Côte d’Ivoire [24] and care should 
be taken not to overinterpret or compare trial data taken 
from different locations or times. Nevertheless, there is a 
significant variation in the loading dose and wash reten-
tion index of PBO in the current brands of pyrethroid-
PBO nets pre-qualified by WHO. There is an urgent need 
for comparative trials of the different brands of pyre-
throid-PBO LLINs in the same location and time in order 
to rank their efficacy or equivalence. The doses applied 
to the different brands should be informed by calibration 
studies designed to determine the dose and the optimal 
bleed rate of PBO required to fully inhibit oxidase-based 
resistance mechanisms in the target vector species.
Apart from the greater killing effect observed with 
VEERALIN® LN, there was a significant reduction in 
human-vector contact resulting from the high blood-
feeding inhibition (60%), deterrence (> 64%), exiting of 
mosquitoes (55–64%) and personal protection (87%). The 
blood-feeding inhibition and personal protection against 
mosquito bites is arguably a more important attribute of 
pyrethroid-PBO LLIN than mortality. While the level of 
protection induced by VEERALIN® LN did not decrease 
with washing, there was a significant decrease in mortal-
ity after 20 standardized washes. Nevertheless, VEERA-
LIN® LN remained superior in terms of mortality to 
MAGNet® LN washed to some extent. The significant 
loss in mortality and maintenance of personal protection 
observed with VEERALIN® LN after washing stresses the 
need for evaluating the durability of PBO net under oper-
ational household conditions. Reduction in mosquito 
mortality occurring after washing is a shortcoming com-
mon to all existing pyrethroid PBO nets. Hut trials with 
PermaNet® 3.0 LN performed in pyrethroid-resistant 
areas in Benin [15] and Côte d’Ivoire [17] showed a sig-
nificant decrease in efficacy after washing both in terms 
of mortality and blood-feeding inhibition with the PBO 
net performing no better than the pyrethroid-only LLIN. 
A typical example is the community trial of Olyset® 
Plus LN in Tanzania: the PBO content under rural con-
dition of use decreased by 83% compared to a decrease 
by only 42% for permethrin after 21  months. Despite 
this decrease in PBO content over this period, a 33% 
reduction in malaria-infection prevalence in children 
protected with Olyset® Plus LN was still observed com-
pared to those living in area covered with Olyset® LN. 
The superior performance of the PBO net Olyset® Plus 
LN was sustained over 21 months of use in the Tanzanian 
study and efficacy is still being monitored to determine 
whether this effect is maintained over the assumed net 
lifespan of three years [21].
Most hut trials evaluating the efficacy of PBO nets 
were conducted in areas where An. gambiae  s.s. is the 
predominant malaria-vector species [15, 17–19]. Hut 
efficacy data of PBO nets against other major malaria 
vectors including An. funestus and An. arabiensis is 
mainly confined to East Africa. In a recent WHOPES-
commissioned hut trial carried out in Ifakara, Tanza-
nia, VEERALIN® LN produced low mortality of An. 
arabiensis and An. funestus, which was not signifi-
cantly different to MAGNet® LN [38]. This contrasts 
with findings from the present study and the differ-
ence in performance of VEERALIN® LN in both coun-
tries could be attributed to the inherent differences 
in behaviour between mosquito vector species, in the 
strength/mechanisms of resistance or to differences in 
hut design used [27].
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Although the present study demonstrated the potential 
of VEERALIN® LN to enhance control and reduce trans-
mission in areas compromised by pyrethroid resistance, 
proof of impact on malaria metrics would ideally require 
large scale cluster randomized trials in a West African 
setting. VEERALIN® LN belongs to the same class of net 
as Olyset® Plus LN. According to the latest WHO rec-
ommendation on deployment of PBO nets, a candidate 
PBO net belonging to the same class of a net for which 
epidemiological data are available does not need to be 
subjected to another CRT [39]. Instead, the effectiveness 
of the candidate PBO net is to be assessed using appro-
priate and relevant entomological endpoints as recently 
set forth by WHO [40]. Following the demonstration by 
the CRT in Muleba, Tanzania, of the benefit of PBO net 
over standard pyrethroid net on malaria metrics, all cur-
rently available PBO nets, have been endorsed by WHO 
[39]. Deployment of PBO net by National Malaria Con-
trol Programmes is now advocated for by WHO in areas 
where resistance is mostly driven by monooxygenase-
based mechanisms. A second CRT currently underway 
in Uganda is evaluating two types of pyrethroid-PBO net 
(PermaNet® 3.0 and Olyset® Plus LLINs) [41]. This trial 
may provide evidence on whether the difference in dose 
and location of PBO between these nets under evaluation 
make any difference to the size of the effect on transmis-
sion. Given the recommendation to endemic countries to 
deploy PBO-based LLIN, it will be necessary to demon-
strate that each type of pyrethroid PBO nets is efficacious 
against metabolic resistant Anopheles mosquitoes. WHO 
now requires that all second-in-class products need to 
demonstrate equivalence to the first-in-class in experi-
mental hut conditions [39, 40]. Studies based on non-
inferiority in experimental hut trials that will generate 
evidence on the relative entomological efficacy of all five 
pyrethroid PBO nets are essential to generate that knowl-
edge and ensure impact.
Conclusions
The pyrethroid-PBO VEERALIN® LN was more effica-
cious than standard pyrethroid-only MAGNet® LN in 
experimental huts both in terms of mosquito mortal-
ity and protection against mosquito bites and therefore 
meets WHO interim approval. The study provides evi-
dence on the potential of PBO nets to enhance control 
of pyrethroid-resistant An. gambiae  s.s. mosquitoes and 
reduce transmission in West Africa.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1307 1-019-3796-x.
Additional file 1: Table S1. Fixed effects in generalised linear mixed 
effect model to evaluate the efficacy of unwashed and 20-times washed 
pyrethroid-PBO and pyrethroid-only LLIN against Anopheles gambiae s.s. 
mosquitoes in MʼBe, Côte d’Ivoire. 
Additional file 2: Table S2. Random effects in generalised linear mixed 
effect model to evaluate the efficacy of unwashed and 20-times washed 
pyrethroid-PBO and pyrethroid-only LLIN against Anopheles gambiae s.s. 
mosquitoes in M’Be, Côte d’Ivoire.
Acknowledgments
The authors would like to thank the volunteer sleepers for participating in the 
experimental hut trial. We are also grateful to the technical staff of VCPEC for 
their contribution to the study. We thank Olivier Pigeon (Gembloux, Belgium) 
for performing the chemical analysis.
Authors’ contributions
RN and MR conceived the study. RN, WO, AK and LA designed the hut trial. 
WO and LA analysed the data. LA and SC supervised the field trial. WO and 
RN wrote the manuscript. MR revised the manuscript. All authors read and 
approved the final manuscript.
Funding
Financial support for the study was obtained from the World Health Organiza-
tion Pesticide Evaluation Scheme (WHOPES) (grant awarded to RN).
Availability of data and materials
All data generated or analysed during this study are included in this published 
article.
Ethics approval and consent to participate
The study was approved by the Ministry of Health in Côte d’Ivoire and the 
Ethical Committee of the London School of Hygiene and Tropical Medicine. 
Adult study volunteers who slept in the huts gave written informed consent 
prior to their participation in the hut trial. Trial participants were examined 
regularly during the course of the study for malaria symptoms by a freelance 
nurse. Sleepers testing positive for malaria were replaced and provided with 
artemisinin-based combination therapy antimalarial drug.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1 London School of Hygiene and Tropical Medicine, Keppel Street, London, UK. 
2 Vector Control Product Evaluation Centre (VCPEC)/Institut Pierre Richet, 01 
BP 1500, Bouaké, Côte d’Ivoire. 
Received: 24 July 2019   Accepted: 7 November 2019
References
 1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. 
The effect of malaria control on Plasmodium falciparum in Africa between 
2000 and 2015. Nature. 2015;526:207–11.
 2. WHO. World malaria report 2018. Geneva: World Health Organization; 
2019.
 3. Bradley J, Ogouyèmi-Hounto A, Cornélie S, Fassinou J, de Tove YSS, 
Adéothy AA. Insecticide-treated nets provide protection against 
malaria to children in an area of insecticide resistance in southern 
Benin. Malar J. 2017;16:225.
 4. Tokponnon FT, Sissinto Y, Ogouyémi AH, Adéothy AA, Adechoubou 
A, Houansou T, et al. Implications of insecticide resistance for malaria 
vector control with long-lasting insecticidal nets: evidence from health 
facility data from Benin. Malar J. 2019;18:37.
Page 9 of 10Oumbouke et al. Parasites Vectors          (2019) 12:544 
 5. N’Guessan R, Corbel V, Akogbéto M, Rowland M. Reduced efficacy 
of insecticide-treated nets and indoor residual spraying for malaria 
control in pyrethroid resistance area, Benin. Emerg Infect Dis. 
2007;13:199–206.
 6. Asidi A, N’Guessan R, Akogbeto M, Curtis C, Rowland M. Loss of house-
hold protection from use of insecticide-treated nets against pyre-
throid-resistant mosquitoes, Benin. Emerg Infect Dis. 2012;18:1101–6.
 7. N’Guessan R, Odjo A, Ngufor C, Malone D, Rowland M, Maxwell C. A 
chlorfenapyr mixture net Interceptor® G2 shows high efficacy and 
wash durability against resistant mosquitoes in West Africa. PLoS ONE. 
2016;11:e0165925.
 8. Bayili K, N’do S, Namountougou M, Sanou R, Ouattara A, Dabiré RK, 
et al. Evaluation of efficacy of Interceptor® G2, a long-lasting insecti-
cide net coated with a mixture of chlorfenapyr and alpha-cyperme-
thrin, against pyrethroid resistant Anopheles gambiae s.l. in Burkina 
Faso. Malar J. 2017;16:190.
 9. Oumbouke WA, Koffi AA, Alou LPA, Rowland M, Guessan RN. Evaluation 
of standard pyrethroid based LNs (MiraNet and MagNet) in experi-
mental huts against pyrethroid resistant Anopheles gambiae s.l. Mʼbé, 
Côte d’Ivoire: potential for impact on vectorial capacity. PLoS ONE. 
2019;14:e0215074.
 10. Bingham G, Strode C, Tran L, Khoa PT, Jamet HP. Can piperonyl butox-
ide enhance the efficacy of pyrethroids against pyrethroid-resistant 
Aedes aegypti? Trop Med Int Health. 2011;16:492–500.
 11. Djouaka RF, Bakare AA, Coulibaly ON, Akogbeto MC, Ranson H, 
Hemingway J, et al. Expression of the cytochrome P450s, CYP6P3 and 
CYP6M2 are significantly elevated in multiple pyrethroid resistant 
populations of Anopheles gambiae s.s. from southern Benin and Nige-
ria. BMC Genomics. 2008;9:538.
 12. Müller P, Warr E, Stevenson BJ, Pignatelli PM, Morgan JC, Steven A, 
et al. Field-caught permethrin-resistant Anopheles gambiae over-
express CYP6P3, a P450 that metabolises pyrethroids. PLoS Genet. 
2008;4:e1000286.
 13. Stevenson BJ, Bibby J, Pignatelli P, Muangnoicharoen S, O’Neill PM, Lian 
L-Y, et al. Cytochrome P450 6M2 from the malaria vector Anopheles 
gambiae metabolizes pyrethroids: Sequential metabolism of deltame-
thrin revealed. Insect Biochem Mol Biol. 2011;41:492–502.
 14. Mitchell SN, Stevenson BJ, Müller P, Wilding CS, Egyir-yawson A, Field 
SG. Identification and validation of a gene causing cross-resistance 
between insecticide classes in Anopheles gambiae from Ghana. Proc 
Natl Acad Sci USA. 2012;109:6147–52.
 15. N’Guessan R, Asidi A, Boko P, Odjo A, Akogbeto M, Pigeon O, et al. An 
experimental hut evaluation of PermaNet(®) 3.0, a deltamethrin-piper-
onyl butoxide combination net, against pyrethroid-resistant Anopheles 
gambiae and Culex quinquefasciatus mosquitoes in southern Benin. 
Trans R Soc Trop Med Hyg. 2010;104:758–65.
 16. Tungu P, Magesa S, Maxwell C, Malima R, Masue D, Sudi W, et al. Evalu-
ation of PermaNet 3.0 a deltamethrin-PBO combination net against 
Anopheles gambiae and pyrethroid resistant Culex quinquefasciatus 
mosquitoes: an experimental hut trial in Tanzania. Malar J. 2010;9:21.
 17. Koudou BG, Koffi AA, Malone D, Hemingway J. Efficacy of PermaNet® 
2.0 and PermaNet® 3.0 against insecticide-resistant Anopheles gambiae 
in experimental huts in Côte d’Ivoire. Malar J. 2011;10:172.
 18. Pennetier C, Bouraima A, Chandre F, Piameu M, Etang J, Rossignol M, 
et al. Efficacy of Olyset® Plus, a new long-lasting insecticidal net incor-
porating permethrin and piperonyl-butoxide against multi-resistant 
malaria vectors. PLoS ONE. 2013;8:e75134.
 19. Toe KH, Müller P, Badolo A, Traore A, Sagnon N, Dabiré RK, et al. Do 
bednets including piperonyl butoxide offer additional protection 
against populations of Anopheles gambiae s.l. that are highly resistant 
to pyrethroids? An experimental hut evaluation in Burkina Faso. Med 
Vet Entomol. 2018;32:407–16.
 20. Churcher TS, Lissenden N, Griffin JT, Worrall E, Ranson H. The impact of 
pyrethroid resistance on the efficacy and effectiveness of bednets for 
malaria control in Africa. Elife. 2016;5:e16090.
 21. Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu 
CD, et al. Effectiveness of a long-lasting piperonyl butoxide-treated 
insecticidal net and indoor residual spray interventions, separately and 
together, against malaria transmitted by pyrethroid-resistant mosqui-
toes: a cluster, randomised controlled, two-by-two factorial design trial. 
Lancet. 2018;391:1577–88.
 22. Gleave K, Lissenden N, Richardson M, Ranson H. Piperonyl butoxide 
(PBO) combined with pyrethroids in long-lasting insecticidal nets 
(LLINs) to prevent malaria in Africa. Cochrane Database Syst Rev. 
2018;11:CD012776.
 23. WHO. Prequalified lists of vector control products. World Health 
Organization; 2019. https ://www.who.int/pq-vecto r-contr ol/prequ alifi 
ed-lists /en/.
 24. Camara S, Koffi AA, Ahoua Alou LP, Koffi K, Kabran JPK, Koné A, et al. 
Mapping insecticide resistance in Anopheles gambiae (s.l.) from Côte 
d’Ivoire. Parasites Vectors. 2018;11:19.
 25. Koffi AA, Ahoua Alou LP, Adja MA, Chandre F, Pennetier C. Insecticide 
resistance status of Anopheles gambiae s.s population from M’Bé: a 
WHOPES-labelled experimental hut station, 10 years after the political 
crisis in Côte d’Ivoire. Malar J. 2013;12:151.
 26. Glunt KD, Coetzee M, Huijben S, Koffi AA, Lynch PA, N’Guessan R, et al. 
Empirical and theoretical investigation into the potential impacts of 
insecticide resistance on the effectiveness of insecticide-treated bed 
nets. Evol Appl. 2017;4(11):431–41.
 27. Oumbouke WA, Fongnikin A, Soukou KB, Moore SJ, N’Guessan R. Rela-
tive performance of indoor vector control interventions in the Ifakara 
and the West African experimental huts. Parasites Vectors. 2017;10:432.
 28. WHO. Review of Spinosad® EC, LifeNet® LN, MagNet LN, Royal Sentry® 
LN, Yahe® LN. WHO/CDS/ NTD/WHOPES/20071. Geneva: World Health 
Organization; 2016. https ://www.who.int/whope s/resou rces/97892 
41502 160/en/.
 29. WHO. Guidelines for laboratory and field testing of long-lasting 
insecticidal nets. WHO/CDS/WHOPES/GCDPP/2005.11. Geneva: World 
Health Organization; 2005. https ://www.who.int/whope s/resou rces/
who_cds_whope s_gcdpp _2005.11/en/.
 30. WHO. Guidelines for laboratory and field testing of long-lasting 
insecticidal mosquito nets. WHO/HTM/NTD/WHOPES/2013.11. Geneva: 
World Health Organization; 2013. https ://www.who.int/whope s/resou 
rces/97892 41505 277/en/.
 31. Pigeon O, Kozuki Y, Fujita T, Mueller M, Patrian B, Pigeon O, et al. CIPAC 
LN Washing method. 8th Joint CIPAC/FAO/WHO Open Meeting. Beijing, 
China; 2011. p. 1–17.
 32. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects 
models using lme4. J Stat Softw. 2014;67:1.
 33. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general para-
metric models. Biom J. 2008;50:346–63.
 34. WHO. Global plan for insecticide resistance management. Geneva: 
World Health Organisation; 2012. https ://www.who.int/malar ia/publi 
catio ns/atoz/gpirm /en/.
 35. Ngufor C, Guessan RN, Fagbohoun J, Todjinou D, Odjo A, Malone D, 
et al. Efficacy of the Olyset Duo net against insecticide-resistant mos-
quito vectors of malaria. Sci Transl Med. 2016;8:3561ra21.
 36. Ngufor C, N’Guessan R, Fagbohoun J, Odjo A, Malone D, Akogbeto 
M, et al. Olyset Duo® (a pyriproxyfen and permethrin mixture net): 
an experimental hut trial against pyrethroid resistant Anopheles 
gambiae and Culex quinquefasciatus in southern Benin. PLoS ONE. 
2014;9:e93603.
 37. Ngufor C, N’Guessan R, Fagbohoun J, Subramaniam K, Odjo A, Fong-
nikin A, et al. Insecticide resistance profile of Anopheles gambiae from 
a phase II field station in Cové, southern Benin: implications for the 
evaluation of novel vector control products. Malar J. 2015;14:464.
 38. WHO. Report of the nineteenth WHOPES working group meeting: 
WHO/HQ, Geneva, 8–11 February 2016. Geneva: World Health Organi-
zation; 2017. https ://www.who.int/whope s/resou rces/97892 41510 400/
en/.
 39. WHO. Conditions for deployment of mosquito nets treated with a pyre-
throid and piperonyl butoxide. Geneva: World Health Organization; 
2017. https ://www.who.int/malar ia/publi catio ns/atoz/use-of-pbo-treat 
ed-llins /en/.
 40. WHO. Data requirements and protocol for determining non-inferiority 
of insecticide-treated net and indoor residual spraying products within 
Page 10 of 10Oumbouke et al. Parasites Vectors          (2019) 12:544 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
an established WHO policy class. Geneva: World Health Organization; 
2018. https ://apps.who.int/iris/handl e/10665 /27603 9.
 41. Staedke SG, Kamya MR, Dorsey G, Maiteki-Sebuguzi C, Gonahasa S, 
Yeka A, et al. LLIN evaluation in Uganda project (LLINEUP)—impact of 
long-lasting insecticidal nets with, and without, piperonyl butoxide on 
malaria indicators in Uganda: study protocol for a cluster-randomised 
trial. Trials. 2019;20:321.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
